XEDEV Email Formats

Research Services • Zele, Flemish Region, Belgium • 11-20 Employees

XEDEV Email Formats

XEDEV uses 2 email formats. The most common is {first initial} (e.g., j@xedev.com), used 64.7% of the time.

Format	Example	Percentage
{first initial}	j@xedev.com	64.7%
{first name}	john@xedev.com	35.3%

Key Contact at XEDEV

Lieselotte De Smet

Chief Technology Officer Cto

Company overview

Headquarters	Poldergotestraat 4, Zele, Vlaanderen 9240, BE
Phone number	+32845352525
Website	xedev.com
NAICS	5417
SIC	283
Keywords	Clinical, Process Development, Formulation, Extrusion, Contract Development, Scale-Up, Coating, gmp, Controlled Release, Inhalation, Spray Drying, Prilling, Agglomeration, Taste Masking, Particle Engineering, Congealing, Fluid Bed, Solubility Enhancement, Vacuum Drying
Founded	2012
Employees	11-20
Socials

About XEDEV

XEDEV is a CRO/CDMO specialised in formulation and process development for solid dosage forms. At XEDEV, we have the capabilities to develop early phase formulations for a very broad range of administration routes as well as formulation analyses by dedicated scientists to have a complete understanding of product quality and stability. XEDEV has a strong formulation and analytical development team, a GMP facility and an appropriate pharmaceutical quality system, enabling manufacturing up to phase IIb. Spray drying is one of our core strenghts. XEDEV follows a phase appropriate development approach for drug product development. Typically, a project is started within 4 to 6 weeks after customer's approval. Flexibility is one of our key strengths together with a direct and transparant communication to the customer. During the project, the customer is always welcome to join the test work in our labs. In summary, XEDEV offers: - formulation and process development of drug products via drying, granulation, tableting and coating processes - different analytical tools to characterize drug substances and drug products (e.g. solid state, powder and tablet characterization, assay and purity analysis) - clincial batch productions up to phase IIb Looking forward to connecting with you!